ImClone’s Erbitux: Approved in Japan For Colorectal Cancer Use
ImClone Systems, Inc.’s advanced colorectal cancer drug has now received regulatory approval in Japan.
ERBITUX(R) (cetuximab) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC).
Specifically, this approval allows for the use of ERBITUX to treat patients with epidermal growth factor receptor (EGFR)-positive, curatively unresectable (inoperable), advanced or recurrent CRC, and allows the use of ERBITUX plus irinotecan in second and further lines of mCRC.
With this approval, ERBITUX is the first ever EGFR-targeted monoclonal antibody to be submitted for and receive marketing authorization in Japan.
ERBITUX (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) — a novel cancer drug developed by ImClone.
Read more from ImClone press release.
Tags: advanced colorectal cancer, colorectal-cancer, Erbitux, ImClone Systems Inc., monoclonal antibodyRelated Stories
POSTED IN: Colon cancer, ~ Anti-cancer treatments ~
0 opinions for ImClone’s Erbitux: Approved in Japan For Colorectal Cancer Use
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: